A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers

Sunil Krishna Halder, R. Daniel Beauchamp, Pran K. Datta

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Small molecule inhibitors of signaling pathways have proven to be extremely useful for the development of therapeutic strategies for human cancers. Blocking the tumor-promoting effects of transforming growth factor-β (TGF-β) in advanced stage carcinogenesis provides a potentially interesting drug target for therapeutic intervention. Although very few TGF-β receptor kinase inhibitors (TRKI) are now emerging in preclinical studies, nothing is known about how these inhibitors might regulate the tumor-suppressive or tumor-promoting effects of TGF-β, or when these inhibitors might be useful for treatment during cancer progression. We have investigated the potential of TRKI in new therapeutic approaches in preclinical models. Here, we demonstrate that the TRKI, SB-431542, inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. We have observed that SB-431542 attenuates the tumor-promoting effects of TGF-β, including TGF-β-induced EMT, cell motility, migration and invasion, and vascular endothelial growth factor secretion in human cancer cell lines. Interestingly, SB-431542 induces anchorage independent growth of cells that are growth-inhibited by TGF-β, whereas it reduces colony formation by cells that are growth-promoted by TGF-β. However, SB-431542 has no effect on a cell line that failed to respond to TGF-β. This represents a novel potential application of these inhibitors as therapeutic agents for human cancers with the goal of blocking tumor invasion, angiogenesis, and metastasis, when tumors are refractory to TGF-β-induced tumor-suppressor functions but responsive to tumor-promoting effects of TGF-β.

Original languageEnglish (US)
Pages (from-to)509-521
Number of pages13
JournalNeoplasia
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2005

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Antineoplastic Agents
Phosphotransferases
Neoplasms
Growth
Cell Movement
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
Cell Line
Therapeutics
Vascular Endothelial Growth Factor A
Carcinogenesis

Keywords

  • EMT VEGF
  • Invasion
  • Metastasis
  • SB-431542
  • TGF-β

ASJC Scopus subject areas

  • Cancer Research

Cite this

A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers. / Halder, Sunil Krishna; Beauchamp, R. Daniel; Datta, Pran K.

In: Neoplasia, Vol. 7, No. 5, 01.01.2005, p. 509-521.

Research output: Contribution to journalArticle

Halder, Sunil Krishna ; Beauchamp, R. Daniel ; Datta, Pran K. / A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers. In: Neoplasia. 2005 ; Vol. 7, No. 5. pp. 509-521.
@article{38135ce61f8548d3871bb8f2c7782032,
title = "A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers",
abstract = "Small molecule inhibitors of signaling pathways have proven to be extremely useful for the development of therapeutic strategies for human cancers. Blocking the tumor-promoting effects of transforming growth factor-β (TGF-β) in advanced stage carcinogenesis provides a potentially interesting drug target for therapeutic intervention. Although very few TGF-β receptor kinase inhibitors (TRKI) are now emerging in preclinical studies, nothing is known about how these inhibitors might regulate the tumor-suppressive or tumor-promoting effects of TGF-β, or when these inhibitors might be useful for treatment during cancer progression. We have investigated the potential of TRKI in new therapeutic approaches in preclinical models. Here, we demonstrate that the TRKI, SB-431542, inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. We have observed that SB-431542 attenuates the tumor-promoting effects of TGF-β, including TGF-β-induced EMT, cell motility, migration and invasion, and vascular endothelial growth factor secretion in human cancer cell lines. Interestingly, SB-431542 induces anchorage independent growth of cells that are growth-inhibited by TGF-β, whereas it reduces colony formation by cells that are growth-promoted by TGF-β. However, SB-431542 has no effect on a cell line that failed to respond to TGF-β. This represents a novel potential application of these inhibitors as therapeutic agents for human cancers with the goal of blocking tumor invasion, angiogenesis, and metastasis, when tumors are refractory to TGF-β-induced tumor-suppressor functions but responsive to tumor-promoting effects of TGF-β.",
keywords = "EMT VEGF, Invasion, Metastasis, SB-431542, TGF-β",
author = "Halder, {Sunil Krishna} and Beauchamp, {R. Daniel} and Datta, {Pran K.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1593/neo.04640",
language = "English (US)",
volume = "7",
pages = "509--521",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers

AU - Halder, Sunil Krishna

AU - Beauchamp, R. Daniel

AU - Datta, Pran K.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Small molecule inhibitors of signaling pathways have proven to be extremely useful for the development of therapeutic strategies for human cancers. Blocking the tumor-promoting effects of transforming growth factor-β (TGF-β) in advanced stage carcinogenesis provides a potentially interesting drug target for therapeutic intervention. Although very few TGF-β receptor kinase inhibitors (TRKI) are now emerging in preclinical studies, nothing is known about how these inhibitors might regulate the tumor-suppressive or tumor-promoting effects of TGF-β, or when these inhibitors might be useful for treatment during cancer progression. We have investigated the potential of TRKI in new therapeutic approaches in preclinical models. Here, we demonstrate that the TRKI, SB-431542, inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. We have observed that SB-431542 attenuates the tumor-promoting effects of TGF-β, including TGF-β-induced EMT, cell motility, migration and invasion, and vascular endothelial growth factor secretion in human cancer cell lines. Interestingly, SB-431542 induces anchorage independent growth of cells that are growth-inhibited by TGF-β, whereas it reduces colony formation by cells that are growth-promoted by TGF-β. However, SB-431542 has no effect on a cell line that failed to respond to TGF-β. This represents a novel potential application of these inhibitors as therapeutic agents for human cancers with the goal of blocking tumor invasion, angiogenesis, and metastasis, when tumors are refractory to TGF-β-induced tumor-suppressor functions but responsive to tumor-promoting effects of TGF-β.

AB - Small molecule inhibitors of signaling pathways have proven to be extremely useful for the development of therapeutic strategies for human cancers. Blocking the tumor-promoting effects of transforming growth factor-β (TGF-β) in advanced stage carcinogenesis provides a potentially interesting drug target for therapeutic intervention. Although very few TGF-β receptor kinase inhibitors (TRKI) are now emerging in preclinical studies, nothing is known about how these inhibitors might regulate the tumor-suppressive or tumor-promoting effects of TGF-β, or when these inhibitors might be useful for treatment during cancer progression. We have investigated the potential of TRKI in new therapeutic approaches in preclinical models. Here, we demonstrate that the TRKI, SB-431542, inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. We have observed that SB-431542 attenuates the tumor-promoting effects of TGF-β, including TGF-β-induced EMT, cell motility, migration and invasion, and vascular endothelial growth factor secretion in human cancer cell lines. Interestingly, SB-431542 induces anchorage independent growth of cells that are growth-inhibited by TGF-β, whereas it reduces colony formation by cells that are growth-promoted by TGF-β. However, SB-431542 has no effect on a cell line that failed to respond to TGF-β. This represents a novel potential application of these inhibitors as therapeutic agents for human cancers with the goal of blocking tumor invasion, angiogenesis, and metastasis, when tumors are refractory to TGF-β-induced tumor-suppressor functions but responsive to tumor-promoting effects of TGF-β.

KW - EMT VEGF

KW - Invasion

KW - Metastasis

KW - SB-431542

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=20344385003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344385003&partnerID=8YFLogxK

U2 - 10.1593/neo.04640

DO - 10.1593/neo.04640

M3 - Article

C2 - 15967103

AN - SCOPUS:20344385003

VL - 7

SP - 509

EP - 521

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 5

ER -